Akari Therapeutics target adjusted to $27 from $1.60 at H.C. Wainwright

H.C. Wainwright adjusted the firm’s price target on Akari Therapeutics (AKTX) to $27 from $1.60 and keeps a Buy rating on the shares. The firm cites the new common shares to U.S share ratio ratio as well as Akari’s capital requirements for the target change.